Showing results (211-220 of 226) with videos related to

Sort By:
Pageof 23
Cancers|October 13, 2021
Light Therapy for Cancer-Related Fatigue in (Non-)Hodgkin Lymphoma Survivors: Results of a Randomized Controlled TrialDaniëlle E J Starreveld, Laurien A Daniels, Jacobien M Kieffer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin LymphomaSuzanne I M Neppelenbroek, Yvonne M Geurts, Berthe M P Aleman, et al.
The Lancet. Haematology|June 27, 2020
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trialNagesh Kalakonda, Marie Maerevoet, Federica Cavallo, et al.
Haematologica|December 1, 2020
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trialMartine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, et al.
Acta Oncologica (Stockholm, Sweden)|December 21, 2020
The eHealth self-management application 'Oncokompas' that supports cancer survivors to improve health-related quality of life and reduce symptoms: which groups benefit most?A van der Hout, K Holtmaat, F Jansen, et al.
Internet Interventions|August 17, 2021
Reasons for not reaching or using web-based self-management applications, and the use and evaluation of Oncokompas among cancer survivors, in the context of a randomised controlled trialA van der Hout, C F van Uden-Kraan, K Holtmaat, et al.
The Lancet. Oncology|December 16, 2019
Role of eHealth application Oncokompas in supporting self-management of symptoms and health-related quality of life in cancer survivors: a randomised, controlled trialAnja van der Hout, Cornelia F van Uden-Kraan, Karen Holtmaat, et al.
Journal of Cancer Survivorship : Research and Practice|July 14, 2020
Cost-utility of an eHealth application 'Oncokompas' that supports cancer survivors in self-management: results of a randomised controlled trialA van der Hout, F Jansen, C F van Uden-Kraan, et al.
ESMO Open|February 13, 2024
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphomaY M Geurts, S I M Neppelenbroek, B M P Aleman, et al.
Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.
Pageof 23